Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineSusan Branford, Timothy P. Hughes, David T Yeung et al.|Blood|2014Cited by 198
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CMLSusan Branford, Timothy P. Hughes, Jodi Prime et al.|Blood|2013Cited by 177
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinibWendy T Parker, Susan Branford, David T Yeung et al.|Blood|2016Cited by 65